The U.S. Food and Drug Administration today approved an expanded indication for the Optune device to treat patients with newly-diagnosed glioblastoma multiforme (GBM), an aggressive form of brain ...
LITTLETON, Colo. (CBS4)- A man with stage 4 brain cancer is beating the odds. Bruce Stahlman has extended his life expectancy with a treatment at UCHealth: a portable, painless device. He wears a ...
Do not use Optune in patients with GBM with an implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with skull defects or ...
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical ...
The FDA has granted approval for Novocure‘s wearable medical device, Optune Lua, designed to treat advanced non-small cell lung cancer (NSCLC). The device utilizes portable transducer arrays placed on ...
SHANGHAI, China and ST. HELIER, Jersey, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative commercial stage biopharmaceutical company, and Novocure (NASDAQ: ...
CLEVELAND — 32-year-old Jonathan Sedor knows a thing or two about climbing over obstacles. He lost his dominant left hand 13 years ago in a firework accident. A few weeks later, he retrained his brain ...
NovoCure makes Optune, a battery-powered device that brain cancer patients wear to prevent cancer cells from multiplying. NovoCure has grown quickly in recent years, but sales of its devices appear to ...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today that the Swiss Federal Office of Public Health (BAG) has added Optune in combination with temozolomide to the List of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results